Company
Mining and Minerals Industries Holdings Pte Ltd
.:[TICKER]
Mining and Minerals Industries Holdings Pte Ltd is focused on the Philippines which has the second largest gold and fourth largest copper reserves in the world. The company is planning a listing on the Singapore Stock Exchange.
170 stories · page 1 of 9
Emyria raises $3 million in well-supported placement
There was strong demand for the placement, including follow-on investment from Tattarang’s Tenmile Ventures and Sixty-Two Capital.
Orthocell secures inclusion for Remplir™ on the prostheses list
“Inclusion of Remplir on the Prostheses List is the culmination of translational research and a regulatory program to bring this product to the Australian market,” said MD Orthocell
Emyria raises $3 million to progress cannabinoid registration and MDMA-analogue development
“We look forward to advancing our clinical programs focused on neuroscience and mental health levering our unique Ultra-Pure cannabinoid formulations, Real-World Data and our substantial drug discovery pipeline inspired by MDMA,” said MD Dr
Emyria and UWA ship 14 new MDMA analogues for screening, total raised to 140-plus proprietary compounds
The company has shipped more MDMA analogues for safety screening, bringing its library to more than 140 novel compounds. EMD has also sent a selection of priority compounds to PsychoGenics in the US to begin advanced preclinical screening,
Orthocell data demonstrates OrthoATI rotator cuff treatment more effective than steroid injections
“I was so fortunate to be involved in this study, and I wish that more people would be able to take advantage of the treatment. It truly has been life-changing for me,” said powerlifting champion Paul Speering.
Orthocell secures first purchase orders for Striate+ and Remplir under new distribution deals
“We are delighted to be working with our Striate+ and Remplir distribution partners to grow adoption and establish our products as best-in-class medical devices,” said Orthocell MD Paul Anderson.
Emyria expands clinical sites for EMD-RX5 Phase 3 trial
Qualified sites are formally approved to participate in core trial activities such as patient recruitment, treatment dosing and clinical assessments.
Emyria begins US-based preclinical program with leading neuroscience drug discovery research organisation
“Given the increasing research and investment into novel neurological drugs and psychedelic-assisted therapies, we are excited to accelerate the identification of promising neuropsychiatric drugs and next-generation psychedelic-assisted the
Orthocell appoints exclusive Australian distributor for Remplir™ nerve repair device
The company is now well-positioned to gain commercial traction with this product in Australia and to expand into the US, the largest global healthcare market in the world.
Emyria fields positive screening results for third batch from MDMA-inspired drug discovery program
“These latest positive screening results will help guide the creation of the next batch of novel MDMA-inspired compounds for our drug discovery portfolio," MD Dr Michael Winlo said.